Mehraboon Irani of Nirmal Bang Securities remains negative on Ranbaxy. He says one should not buy the stock. "I don't see any reasons why Ranbaxy should be going up in a hurry at least from the present levels," he adds.
first published: May 30, 2013 04:51 pm
A collection of the most-viewed Moneycontrol videos.

Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live

Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live

Will Rupee Slide & Expiry Day Caution Keep Nifty Bulls On The Back Foot? | Opening Bell Live

Sensex, Nifty Retreat After Hitting Fresh Highs As Rupee Drops To Record Low| Closing Bell Live
You are already a Moneycontrol Pro user.

